In a unanimous 9-0 ruling, the Supreme Court rejected an attempt to increase restrictions on access to mifepristone, a drug commonly used as part of a two-drug regimen to induce abortions.

The decision, authored by Justice Brett Kavanaugh, concluded the group of anti-abortion doctors who brought the case forward lacked standing to challenge the Food and Drug Administration's (FDA) prior regulatory approval of the pill, the New York Post reported.

Previously censored footage depicts disturbing abortion practices at Planned Parenthood

The Center for Medical Progress (CMP), a pro-life group of citizen journalists, has released another series of disturbing undercover videos that puts the ethical standards of the US' largest… pic.twitter.com/SHZ1pu8dsn

— Rebel News (@RebelNewsOnline) March 28, 2024

Justice Kavanaugh wrote in his opinion, "Those standing allegations suffer from the same problem — a lack of causation. The causal link between FDA's regulatory actions and those alleged injuries is too speculative or otherwise too attenuated to establish standing."

The Supreme Court's decision in FDA v. Alliance for Hippocratic Medicine comes as the most consequential ruling on abortion since the overturn of Roe v. Wade in 2022. The case was closely watched by both pro-life and abortion advocates, as it had the potential to significantly impact access to abortion medications nationwide.

WATCH: Students and staff at Mount Royal University in Calgary oppose anti abortion protest inside the school building. pic.twitter.com/Mh31jROxRf

— Rebel News Canada (@RebelNews_CA) October 31, 2023

During oral arguments in March, the justices expressed deep skepticism about upending the FDA's approval of mifepristone, signaling their reluctance to interfere with the agency's regulatory authority. The unanimous ruling reinforces the FDA's role in determining the safety and efficacy of drugs, including those used in abortion procedures.

The Supreme Court is also currently considering a separate abortion case out of Idaho, highlighting the ongoing legal battles surrounding reproductive rights in the United States following the overturning of Roe v. Wade.

The decision in FDA v. Alliance for Hippocratic Medicine, however, represents a significant victory for advocates of abortion access and a setback for those seeking to impose further restrictions on the procedure.